Factor VII Variant Database last updated on: 02/02/2016

Protein Structures available for Human Coagulation Factor VII

All structural analysis of the mutations presented within this database uses the (2A2Q) that was taken from the Protein Data Bank. Structure 2A2Q consists of active site-inhibited FVIIa in complex with soluble Tissue Factor (Bajaj et al., 2006, PMID: 16757484).


PDB Description In Complex with Resolution Chain Position PDBSum
1BF9 N-terminal EGF-like domain from human Factor VII - A
105-145
>>
1CVW Crystal structure of active site-inhibited human coagulation Factor VIIa (des-Gla) 2.2 H
L
213-466
150-204
>>
1DAN Complex of active site inhibited human blood coagulation Factor VIIa with human recombinant soluble Tissue Factor TF 2 H
L
213-466
61-212
>>
1DVA Crystal structure of the complex between the peptide exosite inhibitor e-76 and coagulation Factor VIIa exosite peptide 3 H/I
L/M
213-466
102-202
>>
1F7E The first EGF-like domain from human blood coagulation FVII - A
105-147
>>
1F7M The first EGF-like domain from human blood coagulation FVII - A
105-147
>>
1FAK Human Tissue Factor complexed with coagulation Factor VIIa inhibited with a bpti-mutant TF 2.1 H
L
213-466
61-212
>>
1FF7 The first EGF-like domain from human blood coagulation FVII (fucosylated at ser-60) - A
105-147
>>
1FFM The first EGF-like domain from human blood coagulation FVII (fucosylated at ser-60) - A
105-147
>>
1J9C Crystal structure of Tissue Factor-Factor VIIa complex TF 2.9 H
L
213-466
108-202
>>
1JBU Coagulation Factor VII zymogen (EGF2/protease) in complex with inhibitory exosite peptide a-183 exosite peptide 2 H
L
213-466
150-212
>>
1KLI CoFactor-and substrate-assisted activation of Factor VIIa 1.6 H
L
213-466
144-212
>>
1KLJ Crystal structure of uninhibited Factor VIIa 2.4 H
L
213-466
144-212
>>
1NL8 Theoretical model of the Tissue Factor/Factor VIIa/Factor xa complex TF - H
M
213-466
61-202
>>
1O5D Dissecting and designing inhibitor selectivity determinants at the s1 site using an artificial ala190 protease (ala190 upa) 2 H
L
213-466
61-212
>>
1QFK Structure of human Factor VIIa and its implications for the triggering of blood coagulation 2.8 H
L
213-466
109-212
>>
1W0Y TF7a_3771 complex - design of selective phenylglycine amide Tissue Factor/Factor VIIa inhibitors TF 2.5 H
L
213-466
61-202
>>
1W2K TF7a_4380 complex - design of selective phenylglycine amide Tissue Factor/Factor VIIa inhibitors TF 3 H
L
213-466
61-202
>>
1W7X Selective and orally bioavailable phenylglycine Tissue Factor/Factor VIIa inhibitors TF 1.8 H
L
213-466
150-204
>>
1W8B Selective and orally bioavailable phenylglycine Tissue Factor/Factor VIIa inhibitors TF 3 H
L
213-466
148-204
>>
1WQV Crystal structure of human Factor VIIa/Tissue Factor in complex with peptide mimetic inhibitor TF 2.5 H
L
213-466
61-212
>>
1WSS Human Factor VIIa-Tissue Factor in complex with peprid mimetic inhibitor that has two charge groups in p2 and p4 TF 2.6 H
L
213-466
61-212
>>
1WTG Human Factor VIIa-Tissue Factor complexed with ethylsulfonamide-d-biphenylalanine-gln-p-aminobenzamidine TF 2.2 H
L
213-466
61-212
>>
1WUN Human Factor VIIa-Tissue Factor complexed with ethylsulfonamide-d-trp-gln-p-aminobenzamidine TF 2.4 H
L
213-466
61-212
>>
1WV7 Human Factor VIIa-Tissue Factor complexed with ethylsulfonamide-d-5-propoxy-trp-gln-p-aminobenzamidine TF 2.7 H
L
213-466
61-212
>>
1YGC Short Factor VIIa with a small molecule inhibitor 2 H
L
213-466
150-212
>>
1Z6J Crystal structure of a ternary complex of Factor VIIa/Tissue Factor/pyrazinone inhibitor TF 2 H
L
213-466
61-202
>>
2A2Q Complex of Active-site Inhibited Human Coagulation Factor VIIa with Human Soluble Tissue Factor TF 1.8 H
L
213-466
61-212
>>
2AEI The discovery of fluoropyridine-based inhibitors of the Factor VIIa/TF complex TF 2.5 H
L
213-466
61-212
>>
2AER Crystal structure of benzamidine-Factor VIIa/soluble Tissue Factor complex TF 1.8 H
L
213-466
61-202
>>
2B7D Factor VIIa-Tissue Factor (FVIIa.TF) complex inhibitors TF 2.2 H
L
213-466
61-212
>>
2B8O Crystal structure of glu-gly-arg-chloromethyl ketone-Factor VIIa/soluble Tissue Factor complex TF 2.8 H
L
213-466
61-202
>>
2BZ6 Orally available Factor7a inhibitor 1.6 H
L
213-466
150-202
>>
2C4F The discovery of fluoropyridine-based inhibitors of the Factor VIIa/TF complex TF 1.7 H
L
213-466
61-202
>>
2EC9 Crystal structure analysis of human Factor VIIa 2 H
L
213-466
61-202
>>
2F9B Discovery of novel heterocyclic Factor VIIa inhibitors 2.5 H
L
213-466
61-212
>>
2FIR Crystal structure of dfpr-VIIa/sTF TF 2 H
L
213-466
61-202
>>
2FLB Novel 5-azaindole Factor VIIa inhibitors 1.9 H
L
213-466
61-212
>>
2FLR Human Factor VIIa-Tissue Factor complexed with benzylsulfonamide-d-ile-gln-p-aminobenzamidine TF 2.3 H
L
213-466
61-212
>>
2PUQ Human Factor VIIa-Tissue Factor complexed with highly selective peptide inhibitor TF 2 H
L
213-466
109-202
>>
2ZP0 Human Factor VIIa-Tissue Factor complexed with benzylsulfonamide-d-ile-gln-p-aminobenzamidine TF 2.7 H
L
213-466
61-212
>>
2ZWL Human Factor VIIa-Tissue Factor complexed with highly selective peptide inhibitor TF 2.2 H
L
213-466
61-212
>>
2ZZU Design and synthesis of peptidomimetic Factor VIIa inhibitors 2.5 H
L
213-466
61-212
>>
3ELA Crystal structure of active site inhibited coagulation Factor VIIa mutant in complex with soluble Tissue Factor TF 2.2 H
L
213-466
61-212
>>
3TH2 Gamma-carboxyglutamic acid (Gla) domains of vitamin k-dependent clotting Factors at physiological Ca2+ 1.7 H
L
213-466
61-202
>>
3TH3 Gamma-carboxyglutamic acid (Gla) domains of vitamin k-dependent clotting Factors at physiological Ca2+ 2.7 H
L
213-466
61-202
>>
3TH4 Gamma-carboxyglutamic acid (Gla) domains of vitamin k-dependent clotting Factors at physiological Ca2+ 1.8 H
L
213-466
61-202
>>
4IBL Rubidium Sites in Blood Coagulation Factor VIIa in complex with Tissue Factor TF 1.8 H
L
213-466
61-212
>>
4ISH Structure of FACTOR VIIA in complex with the inhibitor BMS-593214, a potent, selective FVIIa inhibitor hydrolase inhibitor 1.8 H
L
213-416
150-204
>>
4ISI Design and synthesis of bicyclic pyrazinone and pyrimidinone amides as potent TF-FVIIa inhibitors TF 1.9 H
L
213-466
150-204
>>
4JYU Nonbenzamidine acylsulfonamide Tissue Factor-Factor VIIa inhibitors TF 1.8 H
L
213-466
150-204
>>
4JYV Nonbenzamidine acylsulfonamide Tissue Factor-Factor VIIa inhibitors TF 2.1 H
L
213-466
150-204
>>
4JZD Nonbenzamidine acylsulfonamide Tissue Factor-Factor VIIa inhibitors TF 2.2 H
L
213-466
150-204
>>
4JZE Discovery of nonbenzamidine Factor VIIa inhibitors using a biaryl acid scaffold 1.5 H
L
213-466
150-204
>>
4JZF Discovery of nonbenzamidine Factor VIIa inhibitors using a biaryl acid scaffold 1.8 H
L
213-466
150-204
>>
4NA9 Tetrahydroquinoline derivatives as potent and selective Factor XIa inhibitors 2.2 H
L
213-466
150-204
>>
4NG9 Design and synthesis of phenylpyrrolidine phenylglycinamides as highly potent and selective TF-FVIIa inhibitors TF 2.2 H
L
213-466
150-204
>>
4NGA Design and synthesis of phenylpyrrolidine phenylglycinamides as highly potent and selective TF-FVIIa inhibitors TF 2.1 H
L
213-466
150-204
>>
4X8S Factor VIIa in complex with the inhibitor 4-bromo-2-methoxyphenol hydrolase inhibitor 2.1 H
L
213-466
150-204
>>
4X8T Factor VIIa in complex with the inhibitor 3Z8 hydrolase inhibitor 2.2 H
L
213-466
150-204
>>
4X8U Factor VIIa in complex with the inhibitor 3ZB hydrolase inhibitor 2.1 H
L
213-466
150-204
>>
4X8V Discovery of Novel P1 Groups for Coagulation Factor VIIa Inhibition Using Fragment-Based Screening. hydrolase inhibitor 2.5 H
L
213-466
150-204
>>
4YT6 Factor VIIa in complex with the inhibitor 4JY hydrolase inhibitor 2.0 H
L
213-466
148-204
>>
4YT7 Factor VIIa in complex with the inhibitor 4K1 hydrolase inhibitor 2.3 H
L
213-466
148-204
>>
4ZXX Factor VIIa in complex with 4T0 Inhibitor hydrolase inhibitor 2.6 H
L
213-466
150-204
>>
4ZXY Factor VIIa in complex with 4T1 Inhibitor hydrolase inhibitor 2.0 H
L
213-466
150-204
>>